Tirzepatide
Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Who's worth your money for Tirzepatide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 25 scored sellers
$1800 · 1200mg · 99.1% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 20mg · 99.8% purity
Most tested
57 independent COAs on file
$158 · 40mg · 99.9% purity
Average price
$3.95/mg
Sellers
47
45-day trend
-5%
40 of 47 sellers have a current price· 4 stale hidden· 11 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 5d ago · stale
$1.50/mg -62.1% vs avg$1800
1200mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 5d ago · stale
$4.65/mg +17.6% vs avg$465
100mg
- 🇺🇸 Prime Peptides96
✓ verified at source · 1h ago
$1.67/mg -57.8% vs avg$100
60mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · 5d ago · stale
$0.60/mg -84.9% vs avg$359
600mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 5d ago · stale
$1.85/mg -53.2% vs avg$185
100mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 5d ago · stale
$3.33/mg -15.7% vs avg$200
60mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 5d ago · stale
$3.95/mg -0.1% vs avg$158
40mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · 5d ago · stale
$3.33/mg -15.7% vs avg$100
30mg
- Nova Peptides94
via Disclosed Labs · 5d ago · stale
$3.50/mg -11.5% vs avg$350
100mg
no purity - 🇺🇸 Ignite Peptides93
via Disclosed Labs · 5d ago · stale
$5.00/mg +26.5% vs avg$150
30mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Tirzepatide
Get one email when the market actually moves — no newsletter, no noise.
About Tirzepatide
CAS
2023788-19-2
Molecular formula
C225H348N48O68
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide
Typical dose range
2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week)
Half-life
~5 days (~120 hours)
COAs for Tirzepatide
478 third-party tests across 56 vendors. Each card links to the full report.
For
Tirzeppatide
by Reta One Labs· batch TZ201026
For
Tirzepatide
by NG Peptide· batch TRZ60-05
For
Tirzepatide
by VoriLabs· batch TR60-2608-B
For
Tirzepatide
by VoriLabs· batch TR60-2608-A
For
Tirzepatide
by Sunrise Bioresearch· batch GLP230JUL26-01
For
Tirzepatide
by Novaglo Research· batch 5001072226TZ
For
Tirzepatide
by Novaglo Research· batch 5001572326TZ
For
Tirzepatide
by Novaglo Research· batch 5000572226TZ
For
Tirzepatide
by NovaForge Labs· batch LOT-TR-QSCT1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR10-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR30-1
For
Tirzepatide
by Velora Biolabs· batch VBL-TR60-1
For
Tirzepatide
by Novaglo Research· batch 5003071726TZ
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-F
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-D
For
Tirzepatide
by VoriLabs· batch VoriLabs TR60-2607-C
For
Tirzepatide
by Crush Research· batch CR-2XAG-60-2607-Purple
For
Tirzepatide
by jdbioworks· batch 2026-002
For
Tirzepatide
by Artisan Aminos· batch AA-TRZ220-049
For
Tirzeptide
by Ignite Peptides· batch IP-2607-127
For
Tirzepatide
by Ignite Peptides· batch IP-2607-797
For
Tirzepatide
by Certified Peptides· batch TIR070226
For
Tirzepatide
by VoriLabs· batch TR60-2606-A
For
Tirzepatide
by NG Peptide· batch TRZ40-15
23 citations indexed for Tirzepatide
cohort · 2026
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness.
Study · 2026
Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort
Objective To assess early renal and lithium-related safety and 12-month renal biomarker trajectories after tirzepatide initiation in lithium-treated adults with bipolar disorder. Methods We retrospectively studied 23 adults at one centre.
cohort · 2026
Dual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty
Purpose Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, whereas semaglutide is selective for the GLP-1 receptor.
animal · 2026
Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
Metabolic stress, hepatic lipid accumulation, and macrophage-associated sterile inflammation are closely involved in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Tirzepatide improves metabolic outcomes, but its effects on macrophage inflammatory signaling in MASLD remain unclear.
Study · 2026
Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Study · 2026